94 research outputs found
Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.
Rationale and Design of a Randomized, Double-Blind, Placebo Controlled Multicenter Trial to Study Efficacy, Security, and Long Term Effects of Intermittent Repeated Levosimendan Administration in Patients with Advanced Heart Failure: LAICA study
Effects of Impella on Coronary Perfusion in Patients With Critical Coronary Artery Stenosis
PHARMACOKINETICS AND REGIONAL ELECTROPHYSIOLOGICAL EFFECTS OF INTRACORONARY AMIODARONE ADMINISTRATION
Background The reason for the delay in onset of the electrophysiological
effects and antiarrhythmic efficacy of amiodarone is not clear. The
relation between the development of the electrophysiological effects of
amiodarone and its myocardial concentration is unknown. We therefore
examined the time course of development of electrophysiological effects
during intracoronary infusion of amiodarone and related these changes to
myocardial concentrations.
Methods and Results Amiodarone (0.139 mg/min) or normal saline was
infused for 10 hours into the proximal left anterior descending coronary
artery of 24 open-chest dogs. Nineteen animals received intracoronary
amiodarone and 5 received normal saline (control group). Ten of the 19
that received amiodarone underwent electrophysiological study (amio-EPS
group). Sixteen of the 19, including 7 from the amino-EPS group,
underwent pharmacological study (PS group). In the amio-EPS group during
pacing at a cycle length of 300 ms, changes in conduction velocities in
drug-exposed myocardium referenced to nonexposed myocardium at 1 hour of
infusion were -3.7% in the longitudinal direction (P=NS) and -7.2% in
the transverse direction (P<.05); at 3 hours, -12.9% (P<.05) and -9.1%
(P<.05); and at 9 hours, -32.9% (P<.02) and -31.7% (P<.01). These
changes were dependent on amiodarone concentration (R(2)=.83). There was
also an obvious rate-dependent effect that was more pronounced for
transverse conduction velocities. This effect was also dependent on
amiodarone concentration. In the PS group, amiodarone levels in the
drug-exposed myocardium increased from a mean of 5.95 mug/g at 15
minutes of infusion to 188.88 mug/g at the 10th hour. This increase was
time dependent (R(2)=.91). In the nonexposed myocardium, amiodarone
levels were always low and increased minimally over time from a mean of
2.68 to 14.45 mug/g. This increase was also time dependent (R(2)=.97).
Conclusions Selective intracoronary amiodarone infusion resulted in
selective drug accumulation and concomitant time-dependent reduction of
myocardial conduction velocity. There was a significant correlation
between the extent of reduction of conduction velocity and myocardial
amiodarone concentration but not coronary arterial or systemic
concentration. Repolarization was not significantly altered
COUNTERPULSATION - HISTORICAL BACKGROUND, TECHNICAL IMPROVEMENTS, HEMODYNAMIC AND METABOLIC EFFECTS
The intraaortic balloon counterpulsation is performed today on the same
principles that were described in its first experimental use in 1962.
Experimental studies have shown significant increase of the mean aortic
diastolic pressure, the diastolic pressure-time index, endocardial
viability ratio, cardiac output, ejection fraction, coronary cerebral
and renal blood flow, lactate utilization and myocardial oxygen supply
and significant decrease of the systolic aortic pressure,
left-ventricular end-diastolic pressure, left-ventricular work, tension
time index, myocardial oxygen consumption and lactate production. In
similar studies, intraaortic balloon pump (IABP) decreases the size of
myocardial infarction. New IABP driving systems, small size sheaths and
balloon catheters for percutaneous insertion made the use of the IABP
easier and safer. The paraaortic counterpulsation device is suitable for
chronic mechanical assistance. It is more effective than the IABP and
shows excellent biocompatibility in chronic experiments. Its clinical
application in 3 patients showed excellent biocompatibility and
promising hemodynamic effects. In conclusion, the salutary hemodynamic
effects of the IABP have been shown in several experimental studies. The
technical improvements and the development and use of new devices
suggest that we still need to learn more about the usefulness of the
counterpulsation technique
Post-exercise ST segment elevation preceding myocardial infarction in a patient with nearly normal coronary arteries. A rare form of variant angina
Resuscitation from adrenaline resistant electro-mechanical dissociation facilitated by levosimendan in a young man with idiopathic dilated cardiomyopathy
A 32-year-old man with severe congestive heart failure due to idiopathic
cardionnyopathy developed ventricutar tachycardia followed by
etectromechanical dissociation. High doses of conventional inotropic
medications failed to restore haemodynamics. The additional infusion of
levosimendan in conjunction with external chest compressions for 2.5h
restored haemodynamics, followed by complete recovery, including normal
neurological function. The anti-stunning properties of levosimendan
probably attenuated post-ischaemic myocardial dysfunction and helped to
restore normal cardiac output. (c) 2005 Elsevier Ireland Ltd. All rights
reserved
- …